Abstract
Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Current Drug Safety
Title: Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Volume: 6 Issue: 5
Author(s): Gregory Owens and Andrej Petrov
Affiliation:
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Abstract: Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Export Options
About this article
Cite this article as:
Owens Gregory and Petrov Andrej, Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918692
DOI https://dx.doi.org/10.2174/157488611798918692 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice
Current Drug Metabolism Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Current Pharmaceutical Design An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Anti-inflammatory Sulfur-Containing Agents with Additional Modes of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of IL-5 Receptor Antagonists
Current Pharmaceutical Design State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Structural Organization of the Regulatory Domain of Human 5- Lipoxygenase
Current Protein & Peptide Science Meta-Analysis of Anticancer Drug Structures - Significance of Their Polar Allylic Moieties
Anti-Cancer Agents in Medicinal Chemistry The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Synthesis of Phenyl-substituted Amides with Antioxidant and Antiinflammatory activity as Novel Lipoxygenase Inhibitors
Medicinal Chemistry Therapeutic Management of Atopic Eczema
Current Drug Metabolism Rapid Screening of Different Types of Antitumor Compound Groups from Traditional Chinese Medicine by Hollow Fiber Cell Fishing with High Performance Liquid Chromatography
Combinatorial Chemistry & High Throughput Screening Human Microbiome and Allergic Diseases in Children: Pathogenetic Role and Therapeutic Options
Current Pediatric Reviews Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology